LUNG CANCER How much platinum-based chemotherapy is enough in NSCLC?

被引：5
|
作者：
Peters, Solange [1 ]
Adjei, Alex A. [2 ]
机构：
[1] CHU Vaudois, Dept Oncol, CH-1011 Lausanne, Switzerland
[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2015年 / 12卷 / 01期
关键词：
PHASE-III; RANDOMIZED TRIAL; METAANALYSIS; CISPLATIN; SURVIVAL; DURATION; COURSES; CYCLES;
D O I：
10.1038/nrclinonc.2014.212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
With no large randomized phase III trials to provide definitive answers, the ideal number of platinum-based chemotherapy cycles in patients with advanced non-small-cell lung cancer has long been unclear. Most guidelines recommend a maximum of 4-6 cycles. Rossi and colleagues now suggest that four chemotherapy cycles is the optimal regimen.
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [1] How much platinum-based chemotherapy is enough in NSCLC?
    Solange Peters
    Alex A. Adjei
    Nature Reviews Clinical Oncology, 2015, 12 : 8 - 10
  • [2] Pharmacogenomics of platinum-based chemotherapy in NSCLC
    Hildebrandt, Michelle A. T.
    Gu, Jian
    Wu, Xifeng
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (07) : 745 - 755
  • [3] Markers of response to platinum-based chemotherapy in lung cancer
    Barr, Martin P.
    MacDonagh, Lauren
    O'Byrne, Kenneth J.
    LUNG CANCER MANAGEMENT, 2013, 2 (03) : 227 - 239
  • [4] Resistance to platinum-based chemotherapy in lung cancer cell lines
    Jianli Chen
    Nashwa Emara
    Charalambos Solomides
    Hemant Parekh
    Henry Simpkins
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1103 - 1111
  • [5] Resistance to platinum-based chemotherapy in lung cancer cell lines
    Chen, Jianli
    Emara, Nashwa
    Solomides, Charalambos
    Parekh, Hemant
    Simpkins, Henry
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1103 - 1111
  • [6] COMPARISON OF GEFITINIB AND PLATINUM-BASED CHEMOTHERAPY AND ONLY PLATINUM-BASED CHEMOTHERAPY TO TREAT LUNG ADENOCARCINOMA
    Yang, L.
    Fan, J. H.
    Liu, L. L.
    Su, Y.
    Lu, D.
    Huang, J. Y.
    Zhang, H.
    Li, Y.
    Huo, H. D.
    Du, Z. H.
    Liu, G. T.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2018, 32 (03): : 613 - 618
  • [7] Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients
    Yin, Ji-Ye
    Huang, Qiong
    Zhao, Ying-Chun
    Zhou, Hong-Hao
    Liu, Zhao-Qian
    PLOS ONE, 2012, 7 (06):
  • [8] Is the platinum-based chemotherapy necessary for elderly patients with advanced non-small cell lung cancer (NSCLC)?
    Daga, H.
    Takeda, K.
    Kiyota, H.
    Tokunaga, S.
    Nanjo, S.
    Sumitani, M.
    Shoji, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Molecular profiles of predictive biomarkers for platinum-based chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
    Seyedabadi, NiloofarTaleghani
    Shoushtari, Sara YousefZadeh
    Soofi, Asma
    Arabpour, Javad
    Shams, Zinat
    Akhavan, Homa
    Hosseini-Asl, Saied
    META GENE, 2022, 31
  • [10] Early response to platinum-based chemotherapy in non small cell lung cancer (NSCLC) predicts survival.
    Sirohi, B
    Matakidou, A
    Ashley, S
    Popat, S
    Saka, W
    Priest, K
    Norton, A
    James, M
    Benepal, T
    Eisen, T
    O'Brien, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 672S - 672S
12345